Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 16, 2026

AstraZeneca secures FDA approval for Imfinzi combo in MIBC

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.

AstraZeneca’s research and development site in Gothenburg, Sweden. Credit: AstraZeneca.